Director purchased ~$110K of ADMA shares in the open market

Traded Mar 5, 2026 · Filed Mar 9, 2026

ADMADMA Biologics, Inc.ADMA

~$110K
Approx. value · 7,000 sh @ $15.67: 2.04M
Holds after · shares reported: −35.6%
stock since the trade · S&P 500 +13.7%, $15.70 → $10.11 on Oct 5

Why it stands out

A ADMA Biologics director paid $110K out of pocket for ADMA Biologics shares.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Mar 5, 2026
Reporting period: Not applicable
Filed with the SEC: Mar 9, 2026

DirectorIndirect holding$100K–$500KHoldings +0%

Context

Classification

open market purchase

Code P — open-market or private purchase

Absolute commitment

~$109,690

Shares × reported transaction price

Size band

$100K–$500K

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Ownership change

+0.3%

Purchase shares ÷ estimated pre-transaction holdings, from the filing

Rarity

Not enough history to judge

Confirmed open-market purchases by the same insider in the available history

Cluster activity

No other insider purchases within 30 days

Distinct insiders at the same issuer with confirmed open-market purchases

Timing vs results

8 days after results of Feb 25, 2026, 62 days before results of May 6, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

After it was reported

After	Stock	S&P 500	Difference
7 days	+2.0%	−0.9%	+3.0%
30 days	−37.2%	+0.4%	−37.6%
90 days	−49.1%	+9.2%	−58.2%
180 days	−39.7%	+13.1%	−52.8%

Past results only. Not a forecast.

Source receipt

Record ID: 0001140361-26-008363
Filed / recorded: Mar 9, 2026, 1:14 PM UTC
Added to OQRO: Oct 6, 2026, 9:54 PM UTC
Parser: form4-xml-v2
Data quality: Verified: identifiers matched exactly
Issuer: ADMA BIOLOGICS, INC.
Issuer CIK: 1368514
Ticker: ADMA
Reporting person: Steve Elms
Relationship: Director
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Mar 5, 2026
Transaction code: P
Shares / units: 7,000
Price per share: $15.67
Acquired / disposed: Acquired (A)
Shares owned after: 2,038,730
Ownership form: Indirect — See footnote
Amendment: No

Footnotes from the filing

The reported transaction reflects the open market purchase of shares of ADMA Biologics, Inc. (the "Issuer") common stock. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.58 to $15.74, inclusive.
The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (4) to this Form 4.
Includes (i) 2,031,730 shares owned by Aisling Capital II LP, which is a fund that was established in 2007 with a 10 year life ("Aisling Capital"), and (ii) 14,000 shares owned by Aisling Arcturus Partners, LP ("Aisling Arcturus" and, together with Aisling Capital, "Aisling"), of which 7,000 were purchased on March 5, 2026 and 7,000 were purchased on March 6, 2026. Mr. Elms is Aisling Capital's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of the Issuer's shares owned by Aisling and Aisling Partners' ownership of the Issuer's options, except to the extent of his pecuniary interest therein.